High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction
Rattachement africain : es, gb, de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND PURPOSE: The C-type lectin-like receptor-2 (CLEC-2) is a platelet receptor for the endogenous ligand podoplanin. This interaction contributes to several (patho)physiological processes, such as lymphangiogenesis, preservation of blood and lymphatic vessel integrity organ development, and tumour metastasis. Activation of CLEC-2 leads to the phosphorylation of its cytoplasmic hemITAM domain and initiates a signalling cascade involving the kinase Syk. The aim of this study was to identify and characterise a novel small molecule inhibitor of CLEC-2. EXPERIMENTAL APPROACH: An AlphaScreen-based high-throughput screening was used to identify a small molecule inhibitor of the CLEC-2-podoplanin interaction. Binding site interactions were assessed using in silico modelling. Functional assays, including light transmission aggregometry, platelet spreading and phosphorylation assays, were used to evaluate the effect of a small molecule on CLEC-2-mediated platelet activation. KEY RESULTS: A total of 18,476 small molecules were screened resulting in 14 candidates. Following secondary screening, one novel small molecule, MAS9, was taken forward for further characterisation. The binding sites of MAS9 to CLEC-2 were predicted to share binding sites with the CLEC-2 ligands podoplanin and rhodocytin. MAS9 inhibited CLEC-2-mediated platelet aggregation, spreading and signalling. MAS9 also resulted in inhibited fibrinogen binding. CONCLUSION AND IMPLICATIONS: MAS9 inhibits CLEC-2-mediated aggregation, platelet spreading and signalling, showing selectivity of CLEC-2 inhibition over GPVI. This study paves the way for future preclinical assays to test the potential of MAS9 as a novel therapeutic tool to treat pathologies such as thromboinflammation and cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction
- Date Crossref
- 23/04/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Universidade de Santiago de Compostela Platelet Proteomics Group pays non établi dans la noticeUniversité ou école supérieure
-
Center for Research in Molecular Medicine and Chronic Diseases pays non établi dans la noticeStructure de recherche
-
Instituto de Investigación Sanitaria de Santiago pays non établi dans la noticeStructure de recherche
-
University of Reading Institute for Cardiovascular and Metabolic Research (ICMR) pays non établi dans la noticeUniversité ou école supérieure
-
University of Birmingham Institute of Cardiovascular Sciences pays non établi dans la noticeUniversité ou école supérieure
-
University of Münster pays non établi dans la noticeUniversité ou école supérieure
-
Pivot Park Screening Centre Oss The Netherlands pays non établi dans la noticeInstitution
Platelet Proteomics Group — Universidade de Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases et Instituto de Investigación Sanitaria de Santiago, avec 4 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.